GO
Loading...

Teva Pharmaceutical Industries Ltd

More

  • WASHINGTON, Jan 26- The U.S. Supreme Court on Monday sent three patent cases, including one dispute over Shire Plc's Lialda drug, back to a lower court for further proceedings in light of a ruling the justices issued last week. Watson Pharmaceuticals, U.S. Supreme Court, No. 14-206.. Butamax Advanced Fuels LLC and Lighting Ballast Control LLC v.

  • Midday movers: Teva, Outerwall, Tiffany & more Tuesday, 20 Jan 2015 | 1:16 PM ET

    Some of Tuesday's midday movers:

  • WASHINGTON, Jan 20- The U.S. Supreme Court on Tuesday ruled that Teva Pharmaceutical Industries Ltd can still benefit from patent protection for top-selling multiple sclerosis drug Copaxone, dealing a blow to generic drugmakers looking to market a cheaper rival product. In a 7-2 vote, the justices sent the case back to the U.S. Court of Appeals for the Federal...

  • WASHINGTON, Jan 20- The U.S. Supreme Court on Tuesday ruled for Teva Pharmaceutical Industries Ltd in its fight with generic drug manufacturers over patent protections for Copaxone, its top-selling multiple sclerosis drug, by sending the case back to a lower court for further review. On a 7-2 vote, the justices said that the U.S. Court of Appeals for the Federal...

  • WASHINGTON, Jan 20- The U.S. Supreme Court on Tuesday ruled for Teva Pharmaceutical Industries Ltd in its fight with generic drug manufacturers over patent protections for Copaxone, its top-selling multiple sclerosis drug, by sending the case back to a lower court for further review.

  • Drug pricing concerns? Not at Gilead Monday, 5 Jan 2015 | 10:41 AM ET
    A scientist at Gilead Sciences' laboratory in Foster City, Calif.

    Despite drug pricing concerns that weighed on Gilead Sciences' stock toward the end of December, the drugmaker started the year by raising prices.

  • Jan 5- Staff reviewers at the U.S. Food and Drug Administration recommended approval for Novartis AG's copy of Amgen Inc's blockbuster cancer drug Neupogen. Novartis's drug is the first to be reviewed in the United States under the so-called biosimilar pathway. The reviewers recommended that Novartis's copy should be approved for all the five indications...

  • TEL AVIV, Dec 11- Teva Pharmaceutical Industries forecast 2015 revenue below analysts' expectations, due to adverse foreign exchange moves and generic competition for its best-selling multiple sclerosis treatment Copaxone. There are two teams developing cheaper generic forms of Copaxone: one involving Novartis AG's Sandoz Inc and Momenta...

  • Valeant to drop deal-making to cut debt, lift stock Tuesday, 9 Dec 2014 | 9:00 AM ET
    Valeant Pharmaceuticals sign at the company's headquarters in Mississauga, Ontario.

    Valeant Pharmaceuticals is abandoning its growth-by-acquisitions strategy for the time being to try to reduce debt and boost its stock price.

  • NEW YORK/ WINNIPEG, Dec 9- Valeant Pharmaceuticals International Inc is abandoning its growth-by-acquisitions strategy for the time being to try to reduce debt, boost its stock price and one day return to its traditional deal-making in a stronger position, people familiar with the matter told Reuters. Speculation about Valeant's next takeover target has...

  • NEW YORK/ WINNIPEG, Dec 9- Valeant Pharmaceuticals International Inc is abandoning its growth-by-acquisitions strategy for the time being to try to reduce debt, boost its stock price and one day return to its traditional deal-making in a stronger position, people familiar with the matter told Reuters. Speculation about Valeant's next takeover target has...

  • Dec 5- A Massachusetts jury has found that an agreement between AstraZeneca Plc and Ranbaxy Laboratories Ltd to delay the launch of a generic version of AstraZeneca's heartburn drug Nexium was not anticompetitive. AstraZeneca and an attorney for Ranbaxy released statements saying they were pleased with the verdict. The lawsuit, which began in 2012,...

  • Teva Pharma names Peterburg new chairman Wednesday, 26 Nov 2014 | 1:39 PM ET

    Nov 26- The board of Teva Pharmaceutical Industries Ltd elected Yitzhak Peterburg as its chairman, succeeding Phillip Frost, who is due to step down at the end of the year. The company also appointed Sol Barer, the former chief executive of Celgene Corp, as a director. Teva stock was up 0.8 percent at $57.02 on the New York Stock Exchange.

  • Your first trade for Tuesday Monday, 27 Oct 2014 | 6:33 PM ET
    Fast Money Final Trade: FXC, EWZ, M, TLT

    The "Fast Money" traders share their final trades of the day.

  • Your first trade for Friday Thursday, 2 Oct 2014 | 6:02 PM ET
    Fast Money Final Trade: FXC, EWZ, M, TLT

    The "Fast Money" traders share their final trades of the day.

  • Midday movers: CompuWare, Halliburton, Nike & more Tuesday, 2 Sep 2014 | 1:37 PM ET
    Wall Street New York Stock Exchange NYSE

    Some of Tuesday's midday movers:

  • War and peace, and Israel's stock market Monday, 28 Jul 2014 | 9:07 AM ET
    An Iron Dome short-range missile defense system, positioned near the northern city of Haifa in Israel

    The Israeli stock market is a good test for the old saying that war is good for the economy. Is it investing maxim or enduring myth?

  • Summer's busiest week for markets is here Friday, 25 Jul 2014 | 6:10 PM ET
    Traders work on the floor of the New York Stock Exchange (NYSE) on Friday.

    A crush of big cap earnings and arguably the most important economic reports until September make next week the busiest of the summer for markets.

  • Allergan to shareholders: Ignore Pershing Square Friday, 11 Jul 2014 | 6:31 PM ET
    A vial of Allergan’s Botox is arranged next to boxes for a photograph at a doctor's office in Manhattan Beach, Calif.

    Allergan told its stockholders not to respond to Pershing Square Capital Management's proposal to replace a majority of the board.

  • Midday Movers: GM, Fannie Mae, Apple & more Tuesday, 3 Jun 2014 | 12:28 PM ET
    Traders work the floor of the New York Stock Exchange.

    Take a look at some of Tuesday's midday movers: